BioSpace News Archive

Certara, Inc., a global leader in biosimulation, is adding deep learning capabilities to D360, a leading scientific informatics software platform.

Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) today announced that the company will present a preclinical poster at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting, being held in Salt Lake City, Utah, Mar. 18-21, 2023.

Ocean Biomedical, Inc. Ocean Biomedical’s Scientific Co-founder, Dr. Jack A. Elias, MD, presented details of his previously published discoveries that have potential application for tumor suppression across multiple cancer pathways at the Legorreta Cancer Center’s recent meeting in Providence.

electroCore, Inc. (the “Company”), (NASDAQ: ECOR) a commercial-stage bioelectronic medicine and wellness company, today announced that electroCore’s Chief Strategy Officer, Joshua Lev, will participate in a fireside chat at the 35th Annual Roth Conference in Dana Point, California during March 12-14, 2023.

Spectral Medical Inc. announced the opening of two clinical trials sites, the Medical University of South Carolina and the University of California San Francisco, bringing the total number of active clinical trial sites to 16 for the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock.

Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2022.

Surface Oncology today reported financial results and corporate highlights for the fourth quarter and full year 2022, as well as anticipated near-term corporate milestones.

Foghorn® Therapeutics Inc. today provided a corporate update including the Company’s 2023 strategic priorities and 2022 key achievements in conjunction with its 10-K filing for the year ending December 31, 2022.

Cullinan Oncology, Inc. today reported on recent and upcoming business highlights and announced its financial results for the fourth quarter and full year ended December 31, 2022.

Fulcrum Therapeutics, Inc. today reported financial results for the fourth quarter and full year 2022 and provided a business update, including on FTX-6058.